CR6501A - MODULATION OF EXCITABLE TISSUE FUNCTION THROUGH PERIPHERICALLY ADMINISTRATED Erythropoietin - Google Patents

MODULATION OF EXCITABLE TISSUE FUNCTION THROUGH PERIPHERICALLY ADMINISTRATED Erythropoietin

Info

Publication number
CR6501A
CR6501A CR6501A CR6501A CR6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A CR 6501 A CR6501 A CR 6501A
Authority
CR
Costa Rica
Prior art keywords
erythropoietin
peripherically
administrated
modulation
tissue function
Prior art date
Application number
CR6501A
Other languages
Spanish (es)
Inventor
Brines Michael
Original Assignee
Kenneth S Warren Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Lab filed Critical Kenneth S Warren Lab
Publication of CR6501A publication Critical patent/CR6501A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere al uso de eritropoietina administrada periféricamente y otros moduladores de actividad receptores de eritropoietina o moduladores receptores activados por el EPO para afectar positivamente la función del tejido excitable.It refers to the use of peripherally administered erythropoietin and other erythropoietin receptor activity modulators or EPO activated receptor modulators to positively affect excitable tissue function.

CR6501A 1999-04-13 2001-11-13 MODULATION OF EXCITABLE TISSUE FUNCTION THROUGH PERIPHERICALLY ADMINISTRATED Erythropoietin CR6501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (1)

Publication Number Publication Date
CR6501A true CR6501A (en) 2004-04-15

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6501A CR6501A (en) 1999-04-13 2001-11-13 MODULATION OF EXCITABLE TISSUE FUNCTION THROUGH PERIPHERICALLY ADMINISTRATED Erythropoietin

Country Status (21)

Country Link
EP (1) EP1171147A4 (en)
JP (1) JP2003520194A (en)
KR (2) KR101012932B1 (en)
CN (1) CN1607957B (en)
AU (1) AU784550B2 (en)
BG (1) BG65353B1 (en)
BR (1) BR0009737A (en)
CA (1) CA2383940A1 (en)
CR (1) CR6501A (en)
CZ (1) CZ20013695A3 (en)
EA (1) EA004766B1 (en)
HU (1) HUP0201598A3 (en)
IL (2) IL145895A0 (en)
IS (1) IS6104A (en)
MX (1) MXPA01010177A (en)
NO (1) NO20014991L (en)
NZ (4) NZ560696A (en)
PL (1) PL352223A1 (en)
SK (1) SK14412001A3 (en)
TR (2) TR200103785T2 (en)
WO (1) WO2000061164A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
ATE444077T1 (en) 2000-06-30 2009-10-15 Tokyo Metropolitan Inst Of Ger PREVENTIVES AND THERAPEUTICS FOR DEMYELINIZATION-ASSOCIATED DISEASES
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
DE60219961T8 (en) * 2001-02-02 2008-04-17 Ortho-Mcneil Pharmaceutical, Inc. TREATMENT OF NEUROLOGICAL FUNCTIONAL DISORDERS WITH FRUCTOPYRANOSESULFAMATE AND ERYTHROPOETIN
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ATE542904T1 (en) 2001-10-29 2012-02-15 Crucell Holland Bv METHOD AND MEANS FOR PRODUCING PROTEINS WITH PREDEFINED POST-TRANSLATIONAL MODIFICATIONS
PT1465987E (en) 2001-12-07 2008-04-15 Crucell Holland Bv Production of viruses, viral isolates and vaccines
CN1612747A (en) 2002-01-09 2005-05-04 克鲁塞尔荷兰公司 Use of red blood cell generation promoter in prevention and treatment of heart faiture
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc PROTECTIVE CYTOKINS OF RECOMBINANT TISSUE AND ASSOCIATED ENCODING NUCLEIC ACIDS FOR PROTECTING, RESTORING AND IMPROVING SENSITIVE CELLS, TISSUES AND ORGANS
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004004509B4 (en) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
KR20200075044A (en) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2385746C1 (en) * 2008-07-18 2010-04-10 Владимир Алексеевич Шатров Method of treating infantile cerebral paralysis
RU2432899C1 (en) * 2010-03-23 2011-11-10 Владимир Алексеевич Тупиков Method of predicting recurrence of equinus and equinovarus foot deformations after their early surgery in children with cerebral palsy
RU2519695C2 (en) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (en) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia

Also Published As

Publication number Publication date
EA004766B1 (en) 2004-08-26
WO2000061164A1 (en) 2000-10-19
TR200103785T2 (en) 2002-06-21
CN1607957A (en) 2005-04-20
KR101012932B1 (en) 2011-02-08
CZ20013695A3 (en) 2002-02-13
HUP0201598A2 (en) 2002-09-28
JP2003520194A (en) 2003-07-02
HUP0201598A3 (en) 2002-10-28
AU4348700A (en) 2000-11-14
KR20020000874A (en) 2002-01-05
PL352223A1 (en) 2003-08-11
NZ533098A (en) 2006-04-28
EA200101073A1 (en) 2002-10-31
CN1607957B (en) 2012-10-10
SK14412001A3 (en) 2002-03-05
TR200402194T2 (en) 2004-10-21
IL145895A0 (en) 2002-07-25
CA2383940A1 (en) 2000-10-19
NZ560696A (en) 2010-03-26
IL145895A (en) 2010-05-31
KR100883232B1 (en) 2009-02-10
MXPA01010177A (en) 2004-09-10
IS6104A (en) 2001-10-11
EP1171147A4 (en) 2003-05-14
NZ545478A (en) 2008-04-30
NO20014991L (en) 2001-11-15
AU784550B2 (en) 2006-05-04
BG65353B1 (en) 2008-03-31
KR20070094997A (en) 2007-09-27
NO20014991D0 (en) 2001-10-12
BR0009737A (en) 2003-01-14
NZ514690A (en) 2004-07-30
EP1171147A1 (en) 2002-01-16
BG106058A (en) 2002-12-29

Similar Documents

Publication Publication Date Title
CR6501A (en) MODULATION OF EXCITABLE TISSUE FUNCTION THROUGH PERIPHERICALLY ADMINISTRATED Erythropoietin
FI964323A0 (en) Surgical implant, agent or part thereof
DE60016670D1 (en) Cosmetic agent containing at least one hydroxystilbene and ascorbic acid
CL2004000675A1 (en) USE OF A ANDROGEN COMBINATION OF BIOGENIC OR SYNTHETIC ORIGIN AND A BIOGENIC OR SYNTHETIC ORIGIN STROGEN TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF HYPOGONADISM AND PITUITARIAN HYPOPHISIS OR GLAND DISEASES FOR MEN
ES2192301T3 (en) RESORCINOL DERIVATIVES
ATE336255T1 (en) HYALURONIC ACID ESTER FOR THE TREATMENT OF NORMOTROPHIC SKIN SCARS
DE60107711D1 (en) CONTROLLABLE STRUCTURES FOR SUPPORTING DIAGNOSTIC AND THERAPEUTIC ELEMENTS IN CONTACT WITH BODY TISSUE
CL2004000674A1 (en) TRANSDERMAL THERAPEUTIC SYSTEM THAT UNDERSTANDS AT LEAST AN ACTIVE PHARMACEUTICAL SUBSTANCE, AT LEAST A STRUCTURE DISRUPTOR AND / OR AT LEAST A STRUCTURE FORMATOR IN A COMMON MATRIX.
NO20022998D0 (en) Pharmaceutical preparations which provide increased concentration of drug
YU83600A (en) Adenosine a3 receptor modulators
ATE267613T1 (en) MEDICINAL PRODUCTS AND THEIR USE
PT1196444E (en) CONJUGATES OF EXENDINA-4 AND ITS MEDICAL USES
BR0210631A (en) Extended Release Pharmaceutical Composition
DE59407457D1 (en) BLOCKING THE ADMINISTRATION OF GermS IN HUMAN CELLS
PL353738A1 (en) Composition containing an active substance, production and use thereof
AR017406A1 (en) ABSORBENT DISPOSABLE ARTICLE THAT HAS A MEMBER FOR THE MANAGEMENT OF FECAL MATTERS
BR0206852A (en) Neublastin polymer conjugates and methods for using them
SV2002000062A (en) MONOFLUOROALQUILO DERIVATIVES REF. X-12964
DE60020414D1 (en) Light modulation device, Ansteurungsverfahren thereof, and flat display panel
ES2185317T3 (en) SUPPORT MATERIAL FOR MEDICAL USES.
AR022050A1 (en) COMPOSITIONS OF TENDING BY OXIDATION OF KERATIN FIBERS AND PROCEDURE OF TENDING USING THIS COMPOSITION
AU5157596A (en) Biodegradable device
ATE353642T1 (en) USE OF HYPOESTOXIDES AS ANTIPARASITIVE AGENTS
ES2160044A1 (en) OXIDATION OF * -PINENE.
BR0002772A (en) Use of melatoninergic binders in obtaining pharmaceutical compositions intended for the prevention or treatment of pathologies of the gastrointestinal system

Legal Events

Date Code Title Description
FC Refusal